BioSpace News Archive

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that results of analyses from two clinical studies of seladelpar were delivered during The Liver Meeting Digital Experience™ 2021 (TLMdX) of the American Association for the Study of Liver Diseases (AASLD).

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), today announced updated interim clinical data from the Phase 2 expansion cohort of its ongoing Phase 1/2 clinical trial evaluating ONCT-216 (formerly TK216), an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces the publication of a scientific paper in the peer-reviewed international scientific journal, ACS Pharmacology & Translational Science.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today reported financial results for the quarter ended September 30, 2021 and provided recent business highlights.

Biodesix, Inc. today announced its financial and operating results for the third quarter ended September 30, 2021 and provided a corporate update.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, announced its launch with a proprietary platform technology, three SH2 domain inhibitor programs, and a new chief executive officer, Nancy Whiting, Pharm.D. Series A investors include NEA, Westlake Village BioPartners, and Access Biotechnology.

T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, reported preclinical data demonstrating that its novel MAGE-A1-specific T cell receptor (TCR) induced meaningful anti-tumor activity and enhanced engraftment as compared to human donor derived TCRs. In vivo data presented at the SITC annual meeting highlight the potential of T-knife’s lead product candidate TK-8001.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL 201680005401.3) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the Chinese Patent Office.

NKGen Biotech, a subsidiary of NKMax, harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that data from a Phase 1/2a clinical trial, sponsored by NKMax, evaluating SNK01 (autologous natural killer cells) plus pembrolizumab in Non-Small Cell Lung Cancer (NSCLC) patients in Korea was presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces new data has been published in poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 which took place from 10-14 November 2021 in the US.